Curis warns of potential Nasdaq delisting

Curis, Inc. reports that Nasdaq has issued a Delist Determination Letter because the bid price of its common stock closed below the $1.00 per share minimum for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Curis, Inc. reports that Nasdaq has issued a Delist Determination Letter because the bid price of its common stock closed below the $1.00 per share minimum for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). As a result, Curis’ securities are scheduled for suspension and delisting from the Nasdaq Capital Market at the opening of trading on May 6, 2026, unless the company requests a hearing by May 4, 2026. Curis intends to make a timely hearing request, which would stay further delisting actions, but it cautions there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.

Positive

• None.

Negative

• Nasdaq delisting risk: Curis received a Delist Determination Letter after its stock stayed below the $1.00 bid-price minimum for 30 consecutive business days, and faces suspension and delisting on May 6, 2026 if its planned appeal is not successful.

Insights

Equity markets analyst

Curis faces heightened risk of Nasdaq delisting after bid-price noncompliance.

Curis, Inc. has received a Nasdaq Delist Determination Letter after its stock traded below the $1.00 bid-price requirement for 30 consecutive business days. Because the company is under a one-year Discretionary Panel Monitor, it is not eligible for an automatic cure period.

Instead, trading on the Nasdaq Capital Market is scheduled to be suspended and the shares delisted on May 6, 2026, unless Curis requests a hearing by May 4, 2026. The company plans to seek a new hearing, which would stay delisting actions during the process.

Curis explicitly notes there is no assurance the appeal will be successful or that its stock will remain listed on Nasdaq. For investors, the outcome will directly affect trading venue and potential liquidity, although the filing does not address any impact on the company’s operations.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Bid-price minimum: $1.00 per share Noncompliance period: 30 consecutive business days Scheduled suspension/delisting date: May 6, 2026 +2 more

5 metrics

Bid-price minimum $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Noncompliance period 30 consecutive business days Bid price closed below $1.00 minimum

Scheduled suspension/delisting date May 6, 2026 Planned Nasdaq Capital Market suspension and delisting

Appeal request deadline May 4, 2026 Last date to request Nasdaq hearing to stay delisting

Monitoring period length One-year Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A)

Key Terms

Delist Determination Letter, Discretionary Panel Monitor, Nasdaq Listing Rule 5550(a)(2), Listing Rule 5815(d)(4)(A), +1 more

5 terms

Delist Determination Letter regulatory

"On April 27, 2026, the Company received a Delist Determination Letter from the Staff"

A delist determination letter is a formal notice from a stock exchange telling a company it no longer meets listing rules and is facing removal from the exchange. For investors, it signals that the stock may lose its regular trading venue, which can sharply reduce liquidity and visibility—like being forced out of a busy shopping mall into a small flea market—raising the risk of price drops and harder-to-sell shares.

Discretionary Panel Monitor regulatory

"Curis, Inc. became subject to a Discretionary Panel Monitor for a period of one-year"

A discretionary panel monitor is a compliance mechanism—either a small oversight group or a software tool—that reviews and checks trades made at a manager’s discretion to ensure they follow investment rules, risk limits and client instructions. For investors it matters because this watchdog helps prevent unauthorized or risky decisions, reduces the chance of loss or regulatory penalties, and protects trust much like a referee or speed governor keeps a game or machine within safe limits.

Nasdaq Listing Rule 5550(a)(2) regulatory

"below the minimum $1.00 per share requirement ... pursuant to Nasdaq Listing Rule 5550(a)(2)"

Listing Rule 5815(d)(4)(A) regulatory

"subject to a Discretionary Panel Monitor for a period of one-year pursuant to Listing Rule 5815(d)(4)(A)"

Nasdaq Capital Market market

"continued inclusion on the Nasdaq Capital Market and scheduled for delisting"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Curis (CRIS) receive a Nasdaq Delist Determination Letter?

Curis received the Delist Determination Letter because the bid price of its common stock closed below Nasdaq’s minimum $1.00 per share requirement for 30 consecutive business days under Listing Rule 5550(a)(2), triggering noncompliance with continued listing standards.

When could Curis (CRIS) be suspended and delisted from Nasdaq?

Curis’ securities are scheduled for suspension and delisting from the Nasdaq Capital Market at the opening of trading on May 6, 2026, unless the company timely appeals the delisting determination by requesting a hearing before a Nasdaq Hearings Panel.

What steps is Curis (CRIS) taking in response to the Nasdaq delisting notice?

Curis states that it intends to make a timely request for a new hearing with the initial Nasdaq Hearings Panel, or a newly convened Panel, by May 4, 2026, which would stay further delisting actions while the appeal is considered.

Is there assurance Curis (CRIS) will remain listed on Nasdaq?

Curis explicitly cautions there can be no assurance that its appeal of the Delist Determination Letter will be successful or that the company will remain listed on Nasdaq, even though a timely hearing request would temporarily stay delisting actions.

What is Curis’ current Nasdaq compliance status beyond the bid-price issue?

Curis is under a one-year Discretionary Panel Monitor pursuant to Listing Rule 5815(d)(4)(A). During this period, if it again falls out of compliance with any Nasdaq Listing Rule, the staff cannot grant plan-based compliance periods and instead issues a Delist Determination Letter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:02 PM Learn about SEC filing dates

0001108205false00011082052026-04-272026-04-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): April 27, 2026

Curis, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware			000-30347			04-3505116
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

128 Spring Street, Building C - Suite 500, Lexington, MA 02421

(Address of Principal Executive Offices) (Zip Code)

(617) 503-6500

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:        

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, Par Value $0.01 per share

CRIS

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on February 3, 2026, Curis, Inc. (the “Company”) became subject to a Discretionary Panel Monitor for a period of one-year pursuant to Listing Rule 5815(d)(4)(A). If, within the one-year monitoring period, the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) finds the Company again out of compliance with any of Nasdaq’s Listing Rules, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency, and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Staff will issue a Delist Determination Letter, and the Company will have an opportunity to request a new hearing with the initial Nasdaq Hearings Panel (“Panel”) or a newly convened Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Panel as provided by Listing Rule 5815(d)(4)(C).

On April 27, 2026, the Company received a Delist Determination Letter from the Staff notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), and the Company’s securities will be scheduled for delisting from the Nasdaq Capital Market and suspended at the opening of trading on May 6, 2026 unless the Company timely appeals the Staff’s delisting determination by requesting a hearing before the Panel by May 4, 2026. The Company intends to make a timely request for a new hearing with the initial Panel or a newly convened Panel if the initial Panel is unavailable, which will stay any further delisting actions. However, there can be no assurance that such appeal will be successful or that the Company will remain listed on Nasdaq.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect to the Company’s intent to appeal the Delist Determination Letter, ability to receive a hearing with any Hearings Panel or its ability to suspend or delay its delisting from Nasdaq. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission," or similar expressions. Actual results may differ materially from those indicated by such forward-looking statements. “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings that the Company periodically makes with the SEC. In addition, any forward-looking statements represent the views of the Company only as of the date of the Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any intention or obligation to update any of the forward-looking statements after the date of this Current Report on Form 8-K whether as a result of new information, future events or otherwise, except as may be required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Curis, Inc.
Date:			May 1, 2026			By:			/s/ Diantha Duvall
									Diantha Duvall
									Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB